Brief: Acumen Pharmaceuticals - Expects To Complete Enrollment In Intercept-Ad In Q1 Of 2023 & Anticipates Reporting Topline Data From Trial In Q3 Of 2023
01/02/2023 23:58
Feb 1 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O :
* ACUMEN PHARMACEUTICALS - EXPECTS TO COMPLETE ENROLLMENT IN
INTERCEPT-AD IN Q1 OF 2023 & ANTICIPATES REPORTING TOPLINE DATA
FROM TRIAL IN Q3 OF 2023
Further company coverage: ABOS.O
((Reuters.Briefs@thomsonreuters.com;))